Treatment of HCV-related Liver Diseases after Renal Transplantation: Modern Views

Fabrizi F. , Martin P. , Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38: 919–34.

Pereira B.J.G. , Levey A.S. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981–99.

Vosnides G.G. Nephrology Forum: Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843–61.

Roth D. , Zucker K. , Cirocco R. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45: 238–44.

Chan T.M. , Lok A.S.F. , Chang I.K.P. Hepatitis C in renal transplant recipients. Transplantation 1991; 52: 810–3.

Lau J.Y.N. , Davis G.L. , Brunson M.E. Hepatitis C virus infection in kidney transplant recipients. Hepatology 1993, 18: 1027–31.

Fabrizi F. , Lunghi G. , Marai P. Virological and histological features of hepatitis C virus infection in kidney transplant recipients. Nephrol Dial Transplant 1996; 11: 159–64.

Fabrizi F. , Marai P. , Raffaele L. Hepatitis C virus infection in kidney transplant recipients: a study with second-generation assays. (Letter). Nephrol Dial Transplant 1992; 9: 1164–5.

Fabrizi , Marai P. , Di Filippo S. Hepatitis C virus infection in kidney graft recipients. (Letter). Nephrol Dial Transplant 1992; 7: 274.

Pouteil-Noble C. , Trady J.C. , Chossegros P. Co-infection by hepatitis B and C virus in renal transplantation: morbidity and mortality in 1098 patients. Nephrol Dial Transplant 1995; 10(suppl 6): S122–4.

Berthoux F. Hepatitis C virus infection and disease in renal transplantation. Nephron 1995; 71: 386–94.

Rostaing L. , Izopet J. , Cisterne J.M. Prevalence of antibodies to hepatitis C virus and correlation with liver disease after kidney transplantation. Am J Nephrol 1997; 17: 46–52.

Baur P. , Daniel V. , Pomer S. , Scheurlen H. , Opelz G. , Roelcke D. Hepatitis C virus antibodies in patients after kidney transplantation. Ann Hematol 1991; 62: 68–73.

Klauser R. , Franz O. , Traindl O. Hepatitis C antibody in renal transplant recipients. Transplant Proc 1992; 24: 286–8.

Hestin D. , Hussenet F. , Frimat L. Hepatitis C after renal transplantation: Histopathological correlations. Nephrol Dial Transplant 1996; 11(suppl 4): S52–3.

Glicklich D. , Thung S.N. , Kapoian T. , Tellis V. , Reinus J.F. Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. Am J Gastroenterol 1999; 94: 159–63.

Mahmoud I. , Sobh M.A. , Amer G.M. Prospective study of hepatitis C viremia in renal allograft recipients. Am J Nephrol 1999; 19: 575–85.

Chan T.M. , Lok A.S.F. , Cheng I.K.P. , Chan R.T. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 1993; 104: 862–8.

Ok E. , Unsal A. , Celik A. Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients. Nephrol Dial Transplant 1998; 13: 3103–7.

Rao V.K. , Anderson W.R. , Kasiske B.L. , Dahl D.C. Values of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993; 94: 214–50.

Izopet J. , Rostaing L. , Sandres K. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181: 852–8.

Sandrini S. , Chiappini R. , Setti G. Hepatitis C virus infection after renal transplantation: prevalence and course of morphologic lesions. Transplant Proc 1998; 30: 2100–1.

Alric L. , DI Martino V. , Selves J. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494–9.

Huang C.C. , Liaw Y.F. , Lai M.K. , Chu S.H. , Chuang J.Y. The clinical outcome of hepatitis C virus antibody positive renal allograft recipients. Transplantation 1992; 53: 763–5.

Morales J.M. , Prieto C. , Colina F. , Andres A. , Moreno F. , Rodicio J.L. Does cyclosporin induce clinical remission of dialysis-acquired active chronic hepatitis. (Letter). Nephron 1989; 51: 146–7.

Goffin E. , Pirson Y. , Cornu C. , Geubel A. , Squifflet J.P. , van Ypersele de Strihou C. Outcome of HCV infection after renal transplantation. Kidney Int 1994; 45: 551–5.

Daoud S. , Garnier J.L. , Chossegros P. , Chevallier P. , Dubernard J.M. , Touraine J.C. Hepatitis C virus infection in renal transplantation. Transplant Proc 1995; 27: 1735–7.

Ynares C. , Johnson H.K. , Kerlin T. , Crowe D. , MacDonell R. , Richie R. Impact of pretransplant hepatitis C antibody status upon long-term patients and renal allograft survival – A 5 and 10-year follow-up. Transplant Proc 1993; 25: 1466–8.

Stempel C.A. , Lake J. , Kuo G. , Vincenti F. Hepatitis C – Its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 1993; 55: 273–6.

Ponz E. , Campistol J.M. , Bruguera M. Hepatitis C virus infection among kidney transplant recipients. Kidney Int 1991; 40: 748–51.

Kliem V. , van de Hoff U. , Brunkhorst R. The long-term course of hepatitis C after kidney transplantation. Transplantation 1996; 62: 1417–21.

Mathurin P. , Mouquet C. , Poynard T. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257–63.

Hanafusa T. , Ichikawa Y. , Kishikawa H. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471–6.

Gentil M. , Rocha J.L. , Rodriguez-Algarra G. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14: 2455–60.

Legendre C. , Garrigue V. , Le Biham C. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667–70.

Aroldi A. , Lampertico P. , Elli A. , Lunghi G. , Tarantino A. , Montagnino G. , Colombo M. , Ponticelli C. Long-term evolution of anti-HCV positive renal transplant recipients. Transplant Proc 1998; 30: 1076–8.

Breitenfeldt M.K. , Rasenack J. , Berthold H. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16: 130–6.

Stehman-Breen C.P. , Psaty B.M. , Emerson S. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients. Transplantation 1997; 64: 281–6.

Corell A. , Morales J.M. , Mandrono A. Immunosuppression induced by hepatitis C virus infection reduces acute renal transplant rejection. Lancet 1995; 346: 1497–8.

Knoll G.A. , Tankersley M.R. , Lee J.Y. , Julian B.A. , Curtis J.J. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29: 608–14.

Wolfe R.A. , Ashby V.B. , Milford E.L. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725–30.

Pereira B.J.G. , Natov S.N. , Bouthot B.A. , Murthy B.V.R. , Ruthazer R. , Schmid C.H. , Levey A.S. , and The New England Organ Bank Hepatitis C Study Group. Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998; 53: 1374–81.

Bjoro K. , Froland S. , Yun Z. , Samdal H. , Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immunoglobulin. N Engl J Med 1994; 331: 717–22.

Martin P. , Di Bisceglie A.M. , Kassianides C. , Lisker-Melman M. , Hoofnagle J.H. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989; 97: 1559–61.

Lam K.C. , Lai C.L. , Ng R.P. , Trepo C. , Wu P.C. Deleterious effect of prednisolone in HBsAg positive chronic active hepatitis. N Engl J Med 1981; 303: 380–6.

Zucker R. , Cirocco R. , Roth D. Prospective longitudinal assessment of hepatitis C virus infection after renal transplantation. Transplant Proc 1995; 27: 943–4.

Cheeseman S.H. , Rubin R.H. , Stewart J.A. Controlled clinical trial of prophylactic human-leucocyte interferon in renal transplantation. N Engl J Med 1979; 300: 1345–9.

Hirsch M.A. , Schooley R.T. , Cosimi A.B. Effects of interferon-alpha on cytomegalovirus reactivation syndrome in renal transplant recipients. N Engl J Med 1983; 308: 1489–94.

Kramer P. , Ten-Kate F.W. , Jeekel J. , Bijnen A.B. , Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989–90.

Kovarik J. , Mayer G. , Pohanka E. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejection. Transplantation 1988; 45: 402–5.

Di Bisceglie A.M. , Martin P. , Kassianides C. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 1989; 321: 1506–10.

Davis G.L. , Balart L.A. , Schiff E.R. , and The Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989; 321: 1501–6.

McHutchison J.G. , Gordon S.C. , Schiff E.R. , for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92.

Poynard T. , Marcellin P. , Lee S.S. , for the International Hepatitis Therapy Group. Randomised trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32.

Howell C.D. Current therapy for chronic HCV in general population. Hepatitis C and Renal Disease Workshop, pp. 15-19. Lister Hill Auditorium, National Institute of Health, Bethesda, Maryland (United States), October 21-22, 2002.

Glue P. , Rouzier-Panis R. , Raffanel C. , and The Hepatitis C Intervention Therapy Group. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000; 32: 647–53.

Lindsay K.L. , Trepo C. , Heintges T. , for The Hepatitis Interventional Therapy Group. A randomized, double blind trial comparing PEGylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395–403.

Zeuzem S. , Feinman S.V. , Rasenack J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673–80.

Manns P. , McHutchison J.G. , Gordon S.C. , and The International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65.

Fried M.W. , Shiffman M.L. , Reddy K. Pegylated alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.

Rostaing L. , Izopet J. , Baron E. , Duffaut M. , Pule J. , Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426–31.

Rostaing L. , Modesto A. , Baron E. , Cisterne J.M. , Chabannier M.H. , Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512–6.

Ozgur O. , Boyacioglu S. , Telatar H. , Haberal M. Recombinant α-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 2104–6.

Thervet E. , Pol S. , Legendre C. , Gagnadoux M.F. , Cavalcanti R. , Kreis H. Low dose recombinant leukocyte interferon-α treatment of hepatitis C viral infection in renal transplant recipients. Transplantation 1994; 58: 625–8.

Magnone M. , Holley J.L. , Shapiro R. Interferon-α-induced acute renal allograft rejection. Transplantation 1995; 59: 1068–70.

Ichikawa Y. , Kyo M. , Hanafusa T. A 20-year case study of a kidney transplant recipient with chronic active hepatitis C: clinical course and successful treatment for late acute rejection induced by interferon therapy. Transplantation 1998; 65: 134–8.

Garnier J.L. , Chevalier P. , Dubernard J.M. , Trepo C. , Touraine J.L. , Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 1997; 29: 783.

Rostaing L. Treatment of chronic hepatitis C virus infection following renal transplantation. Hepatitis C and Renal Disease Workshop, pp. 81–84. Lister Hill Auditorium, National Institute of Health, Bethesda, Maryland (United States), October 21-22, 2002.

Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights. Nephrol Dial Transplant 2000; 15: 74–6.

Walsh K.M. , Woodall T. , Lamy P. , Wight D.G. , Bloor S. , Alexander G.J. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49: 436–40.

Lim H.L. , Lau G.K.K. , Davis G.L. , Dolson D.J. , Lau J.Y.N. Progressive cholestatic hepatitis leading to hepatic failure in a patient with organ transmitted hepatitis C virus infection. Gastroenterology 1994; 106: 248–51.

Kroes A. , deMan R. , Niestees H. , Schalm S. , Weimar W. , Balk A. Fatal hepatitis C virus infection in a heart transplant recipient detectable by polymerase chain reaction only. J Hepatol 1994, 21: 1113–5.

Lam P.W.Y. , Wachs M.E. , Somberg K.A. , Vincenti F. , Lake J.R. , Ferrel L.D. Fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation 1996; 61: 387–1.

Munoz De Bustillo E. , Ibarrola C. , Colina F. , Castellano G. , Fuertes A. , Andres A. , Guado J.M. , Rodicio J.L. , Morales J.M. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am Soc Nephrol 1998; 9: 1109–13.

Zylberberg F. , Carnot F. , Mamzer M.F. , Blancho G. , Legendre C. , Pol S. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997; 63: 158–60.

Toth C.M. , Pascual M. , Chung R.T. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1998; 66: 1254–8.